Heidi Henson
About Heidi Henson
Heidi Henson (age 59) has served as an independent director of Perspective Therapeutics, Inc. (CATX) since June 1, 2023. She is a seasoned finance executive and a Certified Public Accountant (inactive), with prior CFO roles across public and private biopharma companies; she is the Board-designated audit committee financial expert. She currently chairs CATX’s Audit Committee and sits on the Compensation and Nominating & Corporate Governance Committees; the Board has affirmed her independence under NYSE American standards .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Pardes Biosciences, Inc. | Chief Financial Officer | Jan 2021–Sep 2023 | Public biopharma CFO experience; led finance through tender offer completion |
| Imbria Pharmaceuticals, Inc. | Chief Financial Officer | 2019–Jul 2020 | Private biopharma CFO experience |
| Respivant Sciences, Inc. | Chief Financial Officer | 2018–2019 | Private biopharma CFO experience |
| Kura Oncology, Inc. | Chief Financial Officer | 2014–2018 | Public biopharma CFO experience |
| Wellspring Biosciences LLC & Araxes Pharma LLC | Chief Financial Officer | 2012–2018 | Private biopharma CFO experience |
External Roles
| Organization | Role | Tenure Status | Committees/Impact |
|---|---|---|---|
| PepGen, Inc. (NASDAQ: PEPG) | Director | Current as of Apr 1, 2025 | Audit Committee Chair (financial oversight) |
| Lisata Therapeutics, Inc. (NASDAQ: LSTA) | Director | Current as of Apr 1, 2025 | Audit Committee Chair (financial oversight) |
Board Governance
- Committee leadership and membership: Henson chairs Audit and is a member of Compensation and Nominating & Corporate Governance .
- Financial expert: Board determined Henson is an “audit committee financial expert” under SEC rules .
- Independence: Board affirmed Henson is independent for Board and Audit Committee under NYSE American standards; also independent for Compensation and Nominating Committees .
- Attendance and engagement: Each director attended at least 75% of Board and applicable committee meetings in FY 2024; Board met 7x, Audit 4x, Compensation 7x, Nominating 2x .
- Annual meeting votes (2025): Henson re-elected with 41,847,883 votes “For,” 10,720,152 “Withheld,” and 8,282,256 broker non-votes; say-on-pay received 38,730,185 “For,” 13,686,122 “Against,” 151,728 “Abstain,” with 8,282,256 broker non-votes .
Fixed Compensation
| Component (2024) | Amount (USD) |
|---|---|
| Fees earned or paid in cash | $75,000 |
| Policy detail | Non-employee directors received $60,000 annual cash retainer; Committee chair additional $15,000; Board Chair additional $30,000 |
Performance Compensation
| Equity Award Terms (2024 Non-Employee Directors) | Details |
|---|---|
| Grant type | Stock options; 23,000 options per director |
| Vesting | 100% on first anniversary of grant |
| Term | 10 years from grant date |
| 2024 Option Grant Fair Value (Henson) | $192,540 (ASC 718) |
| Outstanding options at 12/31/2024 (Henson) | 116,000 |
No director performance-based metrics (TSR/revenue/EBITDA/ESG) are disclosed for director compensation; equity grants are time-vested options rather than PSUs/RSUs .
Other Directorships & Interlocks
- Current public boards: PepGen (PEPG) and Lisata Therapeutics (LSTA) – audit chairs at both .
- Interlocks or related-party exposure: None disclosed involving Henson; Board confirmed independence and reviewed related-party transactions case-by-case via policy (noting Lantheus as a related person due to ownership; no Henson-specific transactions disclosed) .
Expertise & Qualifications
- Education: Bachelor of Accountancy (University of San Diego); CPA (inactive) .
- Technical and governance expertise: Extensive biopharma CFO experience; audit committee financial expert designation; deep financial reporting and oversight acumen .
- Independence and compliance: Determined independent under NYSE American; subject to the Company’s Codes and Insider Trading Policy .
Equity Ownership
| Ownership Detail (Record Date: Apr 2, 2025) | Amount |
|---|---|
| Common shares owned | 25,975 (all held in a trust) |
| Options exercisable within 60 days | 77,340 |
| Percent of class | Less than 1% (based on 74,050,841 shares outstanding) |
| Hedging/Pledging | Prohibited under Insider Trading Policy (no short sales, options, swaps, collars, margin/pledging) |
Insider Trades
| Date | Type | Shares | Price | Holding/Notes | Source |
|---|---|---|---|---|---|
| Dec 4, 2024 | Purchase (P) | 25,975 | $3.85 | Shares held via trust; increased direct beneficial ownership to 25,975 |
Governance Assessment
- Strengths: Independent director; Audit Committee Chair and SEC-designated financial expert; active audit chair roles at two public biotechs; adequate engagement (≥75% attendance) .
- Alignment: Made open-market purchase in Dec 2024; holds all common shares via trust; options outstanding provide long-term alignment; hedging/pledging prohibited by policy .
- Compensation structure: Cash retainer aligned with committee responsibilities; equity is time-vested options (no guaranteed RSUs/PSUs). No director performance metrics disclosed, limiting pay-for-performance signals but typical for small-cap biopharma boards .
- Conflicts/Red flags: No Henson-related party transactions disclosed; Board confirmed independence; Company maintains clawback policy for executives and robust insider trading prohibitions. No pledging/hedging permitted; no director-specific controversies disclosed .
Monitoring items: Continue tracking Form 4 activity for incremental alignment signals; maintain vigilance on Lantheus-related agreements (as a significant holder) though no Henson-specific conflicts are disclosed .